The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55

Journal of NeuroImmune Pharmacology - United States
doi 10.1007/s11481-012-9351-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Synergistic Antinociception by the Cannabinoid Receptor Agonist Anandamide and the PPAR-α Receptor Agonist GW7647

European Journal of Pharmacology
Pharmacology
2007English

GPR55 Regulates Cannabinoid 2 Receptor-Mediated Responses in Human Neutrophils

Cell Research
Cell BiologyMolecular Biology
2011English

Functional Characterization of the Novel Cannabinoid Receptor GPR55 and Its Modulation by CB1 and CB2 Receptors

BMC Pharmacology
2008English

The Putative Cannabinoid Receptor GPR55 Defines a Novel Autocrine Loop in Cancer Cell Proliferation

Oncogene
Cancer ResearchGeneticsMolecular Biology
2010English

Interactions of the G Protein-Coupled Receptor-Associated Sorting Proteins (GASP) 1 and 2 With the Novel Cannabinoid Receptor GPR55

BMC Pharmacology
2008English

The Endogenous Cannabinoid, Anandamide, Inhibits Dopamine Transporter Function by a Receptor-Independent Mechanism

Journal of Neurochemistry
BiochemistryMolecular NeuroscienceCellular
2010English

The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward

Biological Psychiatry
Biological Psychiatry
2014English

Anandamide, an Endogenous Cannabinoid Receptor Ligand, Also Interacts With 5-Hydroxytryptamine (5-Ht) Receptor.

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
1998English

Physiological and Behavioural Effects of the Endogenous Cannabinoid, Arachidonylethanolamide (Anandamide), in the Rat

British Journal of Pharmacology
Pharmacology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy